DCT

1:26-cv-00914

Medac Gesellschaft Fur Klinische Spezialpraparate mbH v. Somerset Therap LLC

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00914, D. Del., 07/24/2026
  • Venue Allegations: Venue is alleged to be proper in the District of Delaware as three of the four defendant entities are organized under the laws of Delaware and thus reside in the district. The fourth defendant is a foreign corporation subject to jurisdiction in the district.
  • Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) for a generic version of the branded drug RASUVO® constitutes an act of infringement of a patent covering concentrated methotrexate solutions for subcutaneous administration.
  • Technical Context: The technology involves high-concentration formulations of methotrexate, a drug used to treat inflammatory autoimmune diseases, which allows for smaller, less painful subcutaneous injection volumes to improve patient compliance.
  • Key Procedural History: This is a Hatch-Waxman action triggered by Defendants' Paragraph IV certification asserting that U.S. Patent No. 8,664,231 is invalid, unenforceable, or will not be infringed by their proposed generic product. The patent-in-suit previously survived an inter partes review (IPR) proceeding (IPR2016-01370), in which all challenged claims (1-22) were found patentable. This lawsuit triggers a 30-month statutory stay on FDA approval of the Defendants' ANDA.

Case Timeline

Date Event
2006-07-21 '231 Patent Priority Date
2013-09-10 Plaintiff's RASUVO® New Drug Application (NDA) Submitted
2014-03-04 '231 Patent Issued
2014-07-10 Plaintiff's RASUVO® NDA Approved by FDA
2016-07-20 Inter Partes Review (IPR2016-01370) Filed Against '231 Patent
2019-09-03 IPR Certificate Issued; Claims 1-22 of '231 Patent Found Patentable
2026-06-10 Defendant's ANDA Submitted (on or before this date)
2026-06-10 Defendant's Paragraph IV Notice Letter Sent
2026-06-12 Plaintiff's Received Paragraph IV Notice Letter (final receipt)
2026-07-24 Complaint Filed
2029-06-01 '231 Patent Expiration Date (earliest)

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,664,231 - Concentrated Methotrexate Solutions

  • Patent Identification: U.S. Patent No. 8,664,231, issued March 4, 2014.

The Invention Explained

  • Problem Addressed: The patent describes that long-term, weekly therapy for rheumatoid arthritis with methotrexate was hampered by patient compliance issues ʼ231 Patent, col. 2:40-44 Oral administration has bioavailability issues, while subcutaneous injections using prior art formulations required injecting large, uncomfortable volumes of fluid due to low drug concentrations (e.g., 10 mg/ml), a particular challenge for children and self-administering patients ʼ231 Patent, col. 2:45-52 ʼ231 Patent, col. 5:1-13
  • The Patented Solution: The invention is a high-concentration methotrexate solution for parenteral (e.g., subcutaneous) administration ʼ231 Patent, abstract By concentrating the drug to "more than 30 mg/ml," and preferably "about 50 mg/ml," the same therapeutic dose can be delivered in a significantly smaller liquid volume, which is expected to be less painful and improve patient compliance ʼ231 Patent, col. 3:18-21 ʼ231 Patent, col. 5:14-23 The patent also describes providing these solutions in ready-to-use devices like syringes or pen injectors to simplify administration ʼ231 Patent, abstract
  • Technical Importance: This high-concentration formulation directly addressed the practical usability challenges of long-term, self-administered methotrexate therapy, making it more tolerable for patients requiring chronic treatment.

Key Claims at a Glance

  • The complaint asserts independent claim 1 and dependent claim 3 Compl. ¶50
  • Independent Claim 1 is a method claim with the following essential elements:
    • A method for the treatment of inflammatory autoimmune diseases in a patient in need thereof, comprising:
    • subcutaneously administering to said patient a medicament comprising methotrexate
    • in a pharmaceutically acceptable solvent
    • at a concentration of more than 30 mg/ml.
  • The complaint's reference to "one or more claims" suggests the right to assert additional claims may be reserved Compl. ¶48

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is Defendants' "Proposed ANDA Product" associated with ANDA No. 221326 Compl. ¶1

Functionality and Market Context

  • The product is a proposed generic version of Plaintiffs' RASUVO® drug Compl. ¶1 It is described as a subcutaneous injection containing methotrexate at a concentration of 50 mg/mL, offered in various dosage strengths Compl. ¶1 Compl. ¶53 The complaint alleges the product's proposed label will substantively copy the RASUVO® label, indicating it for the treatment of severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (pJIA), and severe psoriasis Compl. ¶51 As a generic, it is intended to be a lower-cost, direct substitute for RASUVO®, which has been marketed in the U.S. for over a decade Compl. ¶4 Compl. ¶49

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

'231 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for the treatment of inflammatory autoimmune diseases in a patient in need thereof, comprising: The Proposed ANDA Product's label will be indicated for treating inflammatory autoimmune diseases such as rheumatoid arthritis, pJIA, and psoriasis, mirroring the label for RASUVO®. ¶51; ¶52 col. 8:57-63
subcutaneously administering to said patient a medicament comprising methotrexate The Proposed ANDA Product is a methotrexate solution explicitly intended for subcutaneous administration, as confirmed by Defendants' Paragraph IV Notice Letter. ¶53; ¶54 col. 8:45-46
in a pharmaceutically acceptable solvent The Proposed ANDA Product is a "subcutaneous solution of methotrexate in a pharmaceutically acceptable solvent." ¶53 col. 3:28-36
at a concentration of more than 30 mg/ml. The Proposed ANDA Product will contain methotrexate at a concentration of 50 mg/mL, which is greater than the claimed 30 mg/mL threshold. ¶53 col. 8:47-48

Identified Points of Contention

  • Validity Post-IPR: The complaint alleges Defendants' Paragraph IV letter asserted invalidity but offered no substantive arguments Compl. ¶44 The '231 patent previously survived an IPR challenge where all claims were confirmed as patentable. This raises the question of what basis for invalidity Defendants will now assert, as they must overcome both the patent's presumption of validity and the prior favorable administrative ruling, likely requiring arguments or prior art not considered by the Patent Trial and Appeal Board.
  • Infringement Scope: Given that this is a Hatch-Waxman case where the accused product is intended to be a bioequivalent copy, the infringement analysis appears straightforward. A potential, though likely secondary, dispute could focus on the specific instructions and indications in the final approved product label to confirm they induce infringement of the method claim.

V. Key Claim Terms for Construction

  • The Term: "concentration of more than 30 mg/ml"
  • Context and Importance: This term is the central, defining limitation of the claimed invention, distinguishing it from prior art formulations with lower concentrations. The infringement case hinges on the accused product's 50 mg/mL formulation falling within this claimed range.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The use of the open-ended phrase "more than" suggests any concentration above the 30 mg/ml floor is covered. Dependent claim 2 further specifies a range of "more than 30 mg/mL to 100 mg/mL," and claim 22 recites "from 40 mg/ml to 80 mg/ml," reinforcing that the invention is not limited to a specific value but encompasses a spectrum of higher concentrations ʼ231 Patent, col. 8:49-51 ʼ231 Patent, col. 10:20-22
    • Evidence for a Narrower Interpretation: While a narrowing construction seems unlikely given the plain language, an opponent could point to the preferred embodiment of "about 50 mg/ml" (recited in claim 3 and Example 1) as the core of the invention ʼ231 Patent, col. 8:52-53 ʼ231 Patent, col. 7:43-48 However, the patent's clear "more than" language in the independent claim would present a significant challenge to any argument seeking to limit the claim to a specific concentration.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges both induced and contributory infringement. The inducement theory is based on the allegation that Defendants' proposed product label will instruct and encourage physicians and patients to administer the drug in a manner that directly infringes the method claims Compl. ¶55 Compl. ¶59 The contributory infringement theory alleges the product is not a staple article of commerce and has no substantial non-infringing uses Compl. ¶61
  • Willful Infringement: Willfulness is alleged based on Defendants' knowledge of the '231 patent, which the complaint asserts existed at least as early as the ANDA filing date, and their intent to proceed with the proposed infringing product despite this knowledge Compl. ¶58 Compl. ¶69

VII. Analyst's Conclusion: Key Questions for the Case

  • A central issue will be one of patent validity: Can the Defendants establish by clear and convincing evidence that the '231 patent's claims are invalid, particularly in light of the fact that all claims previously survived a third-party inter partes review challenge, which significantly strengthens their presumption of validity against arguments based on patents and printed publications?
  • A key secondary issue will be one of induced infringement: While the Defendants' product formulation appears to meet the claim limitations, the case for induced infringement will formally depend on whether the final, FDA-approved label for the proposed generic product directs users to perform the patented method of administration for the claimed indications.
Loading Complaint